Shorter TB Regimen Misses the Mark
Shorter high-dose rifampicin regimens proved safe for treating pulmonary tuberculosis (TB), but failed to demonstrate noninferiority compared with the standard 6-month regimen, a phase III trial found. For the primary efficacy outcome, an absolute 6.3% more adults receiving a 4-month regimen that included the highest dose of rifampicin had an unfavorable outcome at 12 to […]